Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

Table 2 Event rates of study outcomes associated with the use of GLP-1ra versus other glucose-lowering agents

	GLP-1ra (n = 1893)	1:1 matched DPP-4i (n = 1893)	GLP-1ra (n = 1829)	1:1 matched SU (n = 1829)	GLP-1ra (n = 1367)	1:1 matched insulin (n = 1367)
Composite CVD^a
Number of events	92	141	83	127	78	171
Total person-years in follow-up	2686.18	3051.80	2669.19	3155.88	1800.99	2595.79
Crude rate (per 1000 person-years)	34.25	46.20	31.10	40.24	43.31	65.88
All-cause mortality
Number of events	1	22	2	6	2	30
Total person-years in follow-up	2755.76	3188.36	2737.90	3275.08	1855.12	2793.32
Crude rate (per 1000 person-years)	0.36	6.90	0.73	1.83	1.08	10.74
Fatal CVD
Number of events	1	13	2	3	1	9
Total person-years in follow-up	2755.76	3188.76	2737.90	3275.21	1855.16	2794.25
Crude rate (per 1000 person-years)	0.36	4.08	0.73	0.92	0.54	3.22
MACE^b
Number of events	28	59	29	43	21	68
Total person-years in follow-up	2740.75	3148.35	2721.35	3235.44	1843.70	2722.47
Crude rate (per 1000 person-years)	10.22	18.74	10.66	13.29	11.39	24.98

CVD cardiovascular disease, DPP-4i dipeptidyl peptidase-4 inhibitor, GLP-1ra glucagon-like peptide-1 receptor agonist, MACE major adverse cardiovascular event, SU sulfonylurea
^aComposite CVD was a composite outcome that included acute myocardial infarction, ischemic heart disease, heart failure, stroke, cardiogenic shock, sudden cardiac arrest, arteriosclerotic cardiovascular disease, and arrhythmia
^bThree-point MACE included non-fatal myocardial infarction, non-fatal stroke, and death due to cardiovascular diseases

ISSN: 1475-2840